CV Therapeutics,
Inc. (Nasdaq: CVTX) announced today that two late breaking clinical trials,
including the MERLIN TIMI-36 study and a regadenoson trial, and six other
abstracts have been accepted for presentation at the American College of
Cardiology (ACC) Annual Scientific Session March 24-27, 2007 in New
Orleans.
The MERLIN TIMI-36 study (Metabolic Efficiency with Ranolazine for Less
Ischemia in Non-ST Elevation Acute Coronary Syndromes) is scheduled for
presentation as a late breaking clinical trial at 8:50 a.m. Central time on
Tuesday, March 27.
The RegEx trial (Multicenter, Randomized, Double-Blind, Placebo and
Active-Controlled Trial of the Safety and Effect on Image Quality and
Detection of Perfusion Defects in Patients Undergoing Regadenoson
Submaximal Exercise Myocardial Perfusion Imaging Versus Adenosine Supine
Myocardial Perfusion Imaging) is scheduled for presentation as a late
breaking clinical trial at 1:45 p.m. Central time on Monday, March 26.
Other accepted abstracts include:
Ranexa(R) (ranolazine extended-release tablets)
-- Long-Term Therapy with Ranolazine Decreases mRNA and Protein Expression
of the Transcriptional Repressor Nab1 and the Transcription Factor Egr1
in Dogs with Chronic Heart Failure; Poster, Sunday, March 25, 9:00 -
10:00 a.m. CDT
-- Ranolazine Normalizes Action Potential Duration of Hypertrophied
Ventricular Cardiomyocytes; Poster, Monday, March 26, 9:00 - 9:50 a.m.
CDT
-- Association Between Recurrent Ischemia on Continuous ECG (Holter)
Monitoring and Short and Long Term Mortality in Patients with Non-ST-
Elevation ACS in the MERLIN TIMI-36 Trial; Poster, Monday, March 26,
2:30 - 3:30 p.m. CDT
Chronic Angina
-- Less is More, None is Better: Angina and Health Related Quality of Life;
Poster, Monday, March 26, 2:30 - 3:30 p.m. CDT
-- Profile of the Patient with Persistent Angina and Significant Coronary
Disease; Oral, Monday, March 26, 4:00 - 4:15 p.m. CDT
Tecadenoson/CVT-3619
-- Ventricular Rate Control in the Goat Model of Atrial Fibrillation:
Synergistic Effects of Metoprolol and Adenosine Receptor Agonists;
Poster, Monday, March 26, 10:00 - 11:00 a.m. CDT
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets), is indicated for the treatment of chronic angina
in patients who have not achieved an adequate response with other
antianginal drugs, and should be used in combination with amlodipine,
beta-blockers or nitrates.
CV Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which is being
developed for potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies and CVT-6883, which is being developed as a
potential treatment for asthma and other conditions. These product
candidates have not been determined by any regulatory authorities to be
safe or effective in humans for any use.
Except for the historical information contained herein, the matters set
forth in this press release are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially, including regulatory review and approval of our products;
special protocol assessment agreement; the conduct, timing and results of
clinical trials, including the MERLIN TIMI-36 study; commercialization of
products; market acceptance of products; product labeling; and other risks
detailed from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements.
CV Therapeutics, Inc.
cvt